AIM2 and systemic lupus erythematosus: B cell‐activating factor (BAFF), which is highly expressed in circulating CD3+ T cells and SLE patients' serum, decreased the expression of AIM2 but increased the levels of p202.105, 106 Therefore, the imbalance between AIM2 regulation and the type I IFN pathway leads to the progress of SLE.